Small Drugmakers Try to Scale Up to Meet Ebola Crisis

October 10, 2014

(Washington Post) – The manufacturer of the experimental Ebola drug ZMapp said Friday that it is trying to squeeze more production out of the tobacco plants used to create the medication and develop other ways of making the drug in an effort to boost supply. The 32,000-square-foot facility in Kentucky where the monoclonal antibodies are created in specially grown tobacco plants has put all other business on hold since August and is devoting its entire capacity to producing the Ebola medication, according to Mapp Biopharmaceutical.